TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Study to assess Pharmacodynamics, Safety, Pharmacokinetics and clinical effects of TAB08 during 12 weeks of treatment in patients with Psoriasis Vulgaris, not adequately controlled with current therapy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Theramab LLC

Criteria

Inclusion Criteria:

• Confirmed diagnosis of Vulgar Psoriasis

• Area of Psoriasis skin damage ≥ 10%

• PASI Score ≥ 12

• Score on IGA scale ≥ 3

Exclusion Criteria:

• Other forms of psoriasis in addition to vulgar

• Prohibited treatment

• Pregnant or nursing women

• Concomitant systemic therapy dosage modification (if any) within 4 weeks before randomization